PET Avidity in Cachexia-Inducing Lung and Gastrointestinal Tumors
Running, not enrolling
Conditions studied: Cachexia; Cancer
In brief
PET has an established role in the initial staging of patients with newly diagnosed lung and gastrointestinal tumors.PET avidity is described with both maximum and mean standardized uptake values.Malignant cells have increased activity on PET, defined as the standardized uptake value (SUV), with increased uptake of FDG in tumor due to elevated levels of GLUT receptors, elevated intracellular levels of hexokinase and increased rates of glycolysis. However, there is a subset of patients with lung and gastrointestinal tumors that are not PET avid.These patients may present with clinically and systemically aggressive disease with a declining performance status and/or weight loss.
Key facts
- Study ID
- NCT03568019
- Run by
- University of Texas Southwestern Medical Center
- People needed
- 10000
- Starts
- 2013-11-26
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-04-21
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with histologically proven lung and gastrointestinal cancers, stages I-IV with PET and/or CT within 6 weeks of diagnosis.
You may not qualify if…
- There will be no absolute exclusion criteria as long as the inclusion criteria have been met.
Where it is running
- UT Southwestern Medical Centre — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.